Allergan profit, sales top estimates; says weighing Valeant offer
May 7 (Reuters) - Allergan Inc reported better-than-expected first- quarter profit on strong sales of Botox and medical devices, and said it was reviewing an unsolicited $47 billion takeover bid from Valeant Pharmaceuticals International Inc.
In its quarterly report, Allergan noted it has in place a one-year stockholder rights plan, commonly called a poison pill, meant to give the company more time to weigh the offer.
Allergan said on Wednesday it earned $257 million, or 85 cents per share, in the quarter. That compared with $12.5 million, or 4 cents, in the year-earlier period, when it took a big charge for discontinued operations.
Excluding special items, Allergan earned $1.18 per share in the recent quarter. Analysts, on average, expected $1.13 per share, according to Thomson Reuters I/B/E/S.
Global sales rose 13 percent to $1.62 billion, topping Wall Street expectations of $1.60 billion. (Reporting by Ransdell Pierson; Editing by Jeffrey Benkoe)
- Israel warns of long Gaza war as Palestinian fighters cross border |
- West agrees wider Russia sanctions as Kiev says forces near crash site |
- Court orders Russia to pay $50 billion for seizing Yukos assets |
- Man found dead trapped between elevator and shaft wall in NYC
- Wall Street yawns as deal news offsets data; Herbalife sinks